Whether BCG strains other than BCG TICE are safe and effective for treating high-grade NMIBC warrants rigorous testing.

For patients with high-risk non–muscle-invasive bladder cancer (NMIBC), the gold-standard systemic therapy for preventing disease recurrence and progression following transurethral resection is ...

The PD-1 inhibitor sasanlimab showed anti-tumor activity and manageable safety in combination with BCG induction and maintenance compared with standard of care in patients with BCG-naïve high-risk ...

ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference ...

Pemetrexed (Pem) plus gemcitabine (Gem) or carboplatin (Carbo) in patients (pts) with advanced malignant mesothelioma (MPM): A randomized phase II trial, E1B03. Background: New treatment options for ...

It is important to note that several reviews carried out in England, Austria, the Czech Republic, and Japan are relatively old and the findings were useful for health decision makers of respective ...

Economic burden of radical cystectomy and trimodal therapy for bladder cancer in the United States: Real-world study. Avelumab first-line maintenance (1LM) in patients (pts) with locally advanced or ...

Study findings fill in the evidence gap during the current BCG shortage, while data from randomized clinical trials are pending. Compared with bacillus Calmette-Guérin (BCG) therapy, sequential ...